TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03367507

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub-symptom aerobic exercise
Description: Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-symptom aerobic exercise
Description: Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
Study: NCT03816995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanCision Wound Retraction and Protection System
Description: wound retraction and irrigation
Study: NCT00186966

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)
Description: See Detailed Description section for details of treatment interventions.
Study: NCT03816995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alexis O Wound Protector
Description: wound retraction
Study: NCT00785317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angemin vs Activelle
Description: 1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angemin vs Activelle
Description: 1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
Study: NCT03503825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Tc-99m]-RPI-T-087 Injection
Description: A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Tc-99m]-RPI-T-087 Injection
Description: A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
Study: NCT03975764

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of fecal sample
Description: Analysis of fecal microbiome

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of fecal sample
Description: Analysis of fecal microbiome
Study: NCT00186966

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan
Description: See Detailed Description section for details of treatment interventions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplant
Description: See Detailed Description section for details of treatment interventions.
Study: NCT01786486

Intervention type: DEVICE
Intervention: Amplatzer Cardiac Plug
Study: NCT01639859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastography
Description: The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
Study: NCT00511979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin
Study: NCT01802255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sedation with inhaled anesthetic via AnaConDa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous sedation.
Study: NCT01319799

Intervention type: OTHER
Intervention: Open heart surgery
Description: TCD count of microembolic signals during surgical aortic valve replacement
Study: NCT01247428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent SES
Description: The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
Study: NCT01105286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
Description: Once daily application
Study: NCT02489110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webnovela

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Study: NCT01683162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic
Description: the lipid of all-in-one, 0.5-3.5g/kg.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipofundin
Description: the lipid of all-in-one, 0.5-3.5g/kg.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study: NCT04580563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OctaplasLG®
Description: Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Study: NCT00186966

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplant
Description: See Detailed Description section for details of treatment interventions.
Study: NCT04580563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Study: NCT04903171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN
Description: Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN
Description: Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
Study: NCT00186966

Intervention type: RADIATION
Group type: OTHER
Intervention: Total body irradiation
Description: See Detailed Description section for details of treatment interventions.

Intervention type: RADIATION
Group type: OTHER
Intervention: Total body irradiation
Description: See Detailed Description section for details of treatment interventions.
Study: NCT00326586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR Antagonist (BMS-641988)
Description: Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
Study: NCT01270217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Description: The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
Study: NCT03760770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal collagen crosslinking
Description: Crosslinking in patients with progressive keratoconus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal collagen crosslinking
Description: Crosslinking in patients with progressive keratoconus.
Study: NCT02515097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Medicated topical lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-122 Vehicle Lotion
Description: Vehicle topical lotion with no active ingredient
Study: NCT03994458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Full version application
Description: Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Samartphone limited version application
Description: Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
Study: NCT00855595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid (Finacea, BAY39-6251)
Description: Participants received topical azelaic acid gel 15% twice daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole (Metrogel)
Description: Participants received topical metronidazole 1% gel once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline (Oracea)
Description: Participants received systemic doxycycline 40 mg once daily for 12 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline (Oracea)
Description: Participants received systemic doxycycline 40 mg once daily for 12 week
Study: NCT03114280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF2
Description: Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy with carboplatin
Description: Radiotherapy (RT) combined with carboplatin
Study: NCT00978965

Intervention type: GENETIC
Intervention: MPA SNP
Description: Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
Study: NCT03962725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Blocking Agents
Description: Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetic Adjuncts
Description: Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
Study: NCT03141099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2.
Description: The patients are randomized to a PaO2 target of 9-10 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2.
Description: The patients are randomized to a PaO2 target of 9-10 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2.
Description: The patients are randomized to a PaO2 target of 9-10 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
Study: NCT02043366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol
Description: Butorphanol is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol
Description: Butorphanol is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated
Study: NCT03749577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline 9g per day (capsule, per os) during 14 days;

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
Study: NCT02043366

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil is intravenously administrated
Study: NCT02167464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin treatment-guided Therapeutics
Description: Patients are treated based upon their renin levels according to an approved algorithm.
Study: NCT03749577

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline placebo
Description: L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
Study: NCT01275508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FITC-Adalimumab
Description: The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
Study: NCT01430403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) \[IU/mL\] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Corticosteroid Boost Therapy (ICS)
Description: Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo omalizumab
Description: Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo omalizumab
Description: Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo fluticasone
Description: Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fluticasone
Description: Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
Study: NCT02410434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGBT Stigma Reduction Intervention
Description: Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
Study: NCT04116658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple dose of EO2401
Description: Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple dose of EO2401
Description: Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple dose of EO2401
Description: Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
Study: NCT04564378

Intervention type: OTHER
Intervention: This is an observational study. There is no therapeutic intervention.
Description: This is an observational study. There is no therapeutic intervention.

Intervention type: OTHER
Intervention: This is an observational study. There is no therapeutic intervention.
Description: This is an observational study. There is no therapeutic intervention.
Study: NCT04375072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS paired with active MBM
Description: Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS paired with active MBM
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2(milli ampere) mA current for 30 seconds. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
Study: NCT03749577

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Denitrated beetroot juice
Description: Concentrated 70 ml nitrate-depleted beetroot juice